The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients
Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease r...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/641 |
| _version_ | 1797318937381175296 |
|---|---|
| author | Osnat Elyashiv Natalie Aleohin Zohar Migdan Sophia Leytes Ofri Peled Ori Tal Tally Levy |
| author_facet | Osnat Elyashiv Natalie Aleohin Zohar Migdan Sophia Leytes Ofri Peled Ori Tal Tally Levy |
| author_sort | Osnat Elyashiv |
| collection | DOAJ |
| description | Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or <6 months after completing first-line platinum-based chemotherapy) and SPR (patients with previously platinum-sensitive disease that developed platinum resistance on subsequent treatments). Clinico-pathological variables and treatment outcomes were compared. Results: Of the 118 patients included in this study, 60 had PPR and 58 developed SPR. The SPR women had a significantly higher rate of optimal debulking during their upfront and interval operations, significantly lower CA-125 levels during their primary treatment, and a significantly higher complete and partial response rate to primary chemotherapy. Once platinum resistance appeared, no significant difference in survival was observed between the two groups. The median PFS was 2 months in the PPR group and 0.83 months in the SPR group (<i>p</i> = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group (<i>p</i> = 0.515). Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival. |
| first_indexed | 2024-03-08T03:59:39Z |
| format | Article |
| id | doaj.art-73e835d7ba92453cbf3430896313b90c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T03:59:39Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-73e835d7ba92453cbf3430896313b90c2024-02-09T15:09:26ZengMDPI AGCancers2072-66942024-02-0116364110.3390/cancers16030641The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer PatientsOsnat Elyashiv0Natalie Aleohin1Zohar Migdan2Sophia Leytes3Ofri Peled4Ori Tal5Tally Levy6Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelTel Aviv Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, IsraelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon 58100, IsraelObjective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR). Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or <6 months after completing first-line platinum-based chemotherapy) and SPR (patients with previously platinum-sensitive disease that developed platinum resistance on subsequent treatments). Clinico-pathological variables and treatment outcomes were compared. Results: Of the 118 patients included in this study, 60 had PPR and 58 developed SPR. The SPR women had a significantly higher rate of optimal debulking during their upfront and interval operations, significantly lower CA-125 levels during their primary treatment, and a significantly higher complete and partial response rate to primary chemotherapy. Once platinum resistance appeared, no significant difference in survival was observed between the two groups. The median PFS was 2 months in the PPR group and 0.83 months in the SPR group (<i>p</i> = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group (<i>p</i> = 0.515). Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival.https://www.mdpi.com/2072-6694/16/3/641recurrent ovarian cancerplatinum resistance |
| spellingShingle | Osnat Elyashiv Natalie Aleohin Zohar Migdan Sophia Leytes Ofri Peled Ori Tal Tally Levy The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients Cancers recurrent ovarian cancer platinum resistance |
| title | The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients |
| title_full | The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients |
| title_fullStr | The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients |
| title_full_unstemmed | The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients |
| title_short | The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients |
| title_sort | poor prognosis of acquired secondary platinum resistance in ovarian cancer patients |
| topic | recurrent ovarian cancer platinum resistance |
| url | https://www.mdpi.com/2072-6694/16/3/641 |
| work_keys_str_mv | AT osnatelyashiv thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT nataliealeohin thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT zoharmigdan thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT sophialeytes thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT ofripeled thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT orital thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT tallylevy thepoorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT osnatelyashiv poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT nataliealeohin poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT zoharmigdan poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT sophialeytes poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT ofripeled poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT orital poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients AT tallylevy poorprognosisofacquiredsecondaryplatinumresistanceinovariancancerpatients |